Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:56:45.850Z.
Calculation as of: 2026-10-06T19:56:45.850Z.
Quote observation: 2026-10-06T19:55:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 463be1a1b995a1dfb9509f80aff3bd03150ce45d2105de53d296fe87a8cca28c
PE RATIO
N/A
Market Cap
$112.11M
PE Ratio
N/A
TTM Avg
26.17
3Y Avg
26.17
5Y Avg
26.17
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $115.08M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.48M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.09M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $113.07M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.74M | N/A | N/A | N/A | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.40M | N/A | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.11M | N/A | 26.17 | 26.17 | 26.17 |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.96
Forward EPS (Est.)
$-0.91
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
